Pharmacokinetic Study on the Combination of Everolimus-Tacrolimus
Status:
Unknown status
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to address the pharmacokinetic (PK) profiles of everolimus and
tacrolimus in combination in de novo kidney transplant recipients, comparing 1.5 and 3 mg per
day of everolimus in fixed doses. For comparison purposes, pharmacokinetic profiles will be
performed at first dose (abbreviated), 4th day, 14th day, and 42nd day post-transplantation.